The short version
What teams need to understand
- Pharmacovigilance vendors must be formally qualified before performing safety activities, ensuring they have the systems, expertise, and compliance controls required to support regulatory obligations.
- Qualification must include documented due diligence, risk assessment, and evaluation of vendor capabilities.
- Vendors must demonstrate compliance with pharmacovigilance regulations, quality systems, and data handling requirements.
- Qualification decisions must be approved by appropriate functions including PV, QA, and the QPPV.
- The level of qualification must be proportionate to the risk and criticality of the service provided.
- Inspection-ready evidence must demonstrate that vendor selection is controlled, justified, and documented.
Regulatory expectation
What regulators expect
Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.
- Vendors must be qualified before performing pharmacovigilance activities.
- Qualification must be based on documented due diligence and risk assessment.
- Vendors must demonstrate capability to comply with regulatory requirements.
- Qualification decisions must be formally approved.
- The MAH must retain responsibility for vendor performance.
Why it matters
What this means in practice
Inspectors assess whether pharmacovigilance vendors are formally qualified before engagement. They typically review due diligence, risk assessments, audit outcomes, and approval decisions to confirm that vendors are capable of performing PV activities in compliance with regulatory requirements.
Questions this page answers
Inspection evidence
Evidence teams should be able to show
Vendor Qualification SOP
- Defined process for vendor identification and qualification
- Roles and responsibilities for PV, QA, and Procurement
- Risk-based qualification approach
- Approval and documentation requirements
Vendor Assessment Questionnaire
- Evaluation of vendor PV processes and experience
- Assessment of quality management system
- Review of regulatory inspection history
- Evaluation of data security and system validation
Risk Assessment Documentation
- Risk classification (high, medium, low)
- Assessment of service criticality
- Evaluation of regulatory impact
- Documented justification of risk level
Pre-Qualification Audit Evidence
- Audit reports for medium or high-risk vendors
- Assessment of PV processes and systems
- Identification of gaps or compliance risks
- Audit conclusions supporting qualification decision
Vendor Qualification Report and Approval
- Summary of vendor strengths and weaknesses
- Decision to approve, conditionally approve, or reject vendor
- QA review and approval
- QPPV or delegated approval of vendor
Approved Vendor List
- List of qualified PV vendors
- Defined services provided by each vendor
- Risk classification and status
- Approval and review dates
Regulatory Basis (Primary Sources)
- GVP Module I - MAH responsibility for pharmacovigilance systems and oversight of third parties
- GVP Module VI - requirements for ensuring compliant handling of safety data
- ICH E2D - post-approval safety data management and vendor responsibilities
- MHRA GPvP guidance - expectations for vendor qualification and oversight
- FDA pharmacovigilance guidance - responsibility for compliance when outsourcing activities
Typical Inspection Questions (What Inspectors Ask)
- How did you qualify this vendor?
- What risk assessment was performed before engagement?
- Show me your vendor qualification documentation.
- Did you audit this vendor before approval?
- Who approved the vendor and on what basis?
Common failure patterns
What good looks like
- Structured and documented vendor qualification process.
- Clear risk-based approach to vendor assessment.
- Evidence of vendor capability and regulatory compliance.
- Audit performed where required and findings addressed.
- Formal approval and documentation of qualification decisions.
How teams operationalise it
- Define a structured vendor qualification process within the PV SOP.
- Use standardised questionnaires to assess vendor capabilities.
- Perform risk assessments based on service criticality.
- Conduct audits for medium and high-risk vendors.
- Document qualification decisions and approvals.
- Maintain an up-to-date approved vendor list.
From expectation to working control
Find the documentation that supports this work
Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.
Frequently asked questions
What is vendor qualification in pharmacovigilance?
Vendor qualification is the process of assessing and approving a third-party provider to ensure they can perform pharmacovigilance activities in compliance with regulatory requirements.
What checks are performed before approving a pharmacovigilance vendor?
Checks typically include review of the vendor’s quality system, pharmacovigilance processes, regulatory inspection history, data security controls, personnel qualifications, and risk assessment, supported by questionnaire responses and audit where required.
When must a vendor be qualified?
A vendor must be qualified before performing any pharmacovigilance activities or handling safety data on behalf of the MAH.
What is included in vendor qualification?
Vendor qualification includes due diligence, risk assessment, review of processes and systems, audit where required, and formal approval.
Do inspectors review vendor qualification processes?
Yes. Inspectors frequently review vendor qualification documentation to confirm that vendors are assessed and approved appropriately.
Is an audit always required for vendor qualification?
Audits are typically required for medium and high-risk vendors, while low-risk vendors may be qualified through documentation and assessment alone.
Who approves vendor qualification in pharmacovigilance?
Vendor qualification is typically approved by PV Operations, Quality Assurance, and the QPPV or delegated authority.
Source boundary
Regulatory sources
These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.
European Medicines Agency (EMA)
Guideline on good pharmacovigilance practices (GVP) - Module I
View sourceGuideline on good pharmacovigilance practices (GVP) - Module VI
View source
FDA
Postmarketing Safety Reporting
View source
ICH
Post-Approval Safety Data Management (E2D)
View source
MHRA
Good Pharmacovigilance Practice (GPvP)
View source